Recent Finacing
Recent Raise
Dantari develops clinical-stage T-HDC and antibody-drug conjugates using chemically defined polymers to achieve high drug-antibody ratios and design-controlled targeted chemotherapeutic conjugates, pipeline led by DAN-222.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
